Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - September 2018

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Denosumab (Prolia®) has been rejected for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - September 2018' on Email Share 'SMC Update - September 2018' on Delicious Share 'SMC Update - September 2018' on Digg Share 'SMC Update - September 2018' on Facebook Share 'SMC Update - September 2018' on reddit Share 'SMC Update - September 2018' on StumbleUpon Share 'SMC Update - September 2018' on Twitter

atomic-wealth

No Comments to “SMC Update - September 2018”

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer